<?xml version="1.0" encoding="UTF-8"?>
<p>During the 2005 SARS outbreak in Hong Kong, Cheng et al [
 <xref rid="R56" ref-type="bibr">56</xref>], have published the most extensive study on the outcomes of 1,775 patients with the infection, of whom, 80 patients received CP had a lower mortality rate (12.5%) compared to overall SARS-related mortality. The study was not a randomized trial, and no adverse events reported [
 <xref rid="R56" ref-type="bibr">56</xref>]. Shen et al [
 <xref rid="R54" ref-type="bibr">54</xref>] have published a preliminary study of five patients with COVID-19 who were severely ill and treated with CP from China. All five patients were mechanically ventilated, and one needed ECMO. The donor CP, an apheresis product, had demonstrable immunoglobulin G (IgG) and IgM anti-SARS-CoV-19 antibodies and 
 <italic>in vitro</italic> virus-neutralizing properties. The authors concluded that the CP might have contributed to the recovery, although the patients were also on lopinavir/ritonavir antiviral therapy and IFN [
 <xref rid="R57" ref-type="bibr">57</xref>].
</p>
